We are live on ! Find out more
CYTH

Cyclo Therapeutics, Inc. Common Stock
CYTH

Delisted

CYTH was delisted on the 25th of March, 2025.

Back to rankings

13 hedge funds and large institutions have $795K invested in Cyclo Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 13 → 13 (0)

42% less capital invested

Capital invested by funds: $1.38M → $795K (-$581K)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
13
Holders Change
–
Holders Change %
0%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
6
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$1.85K
2
Wells Fargo
Wells Fargo
California
+$10

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$43.2K
2
Renaissance Technologies
Renaissance Technologies
New York
-$28.6K
3
UBS Group
UBS Group
Switzerland
-$3.63K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$3.15K
5
Morgan Stanley
Morgan Stanley
New York
-$145

CYTH Hedge Fund Activity: Q2 2022 in Review

13 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Common Stock (CYTH) for Q2 2022, worth a combined $795K — down 42% from $1.38M a quarter earlier.

Fund positioning in CYTH was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 6 trimmed.

The largest buyer was Tower Research Capital (TRC), adding an estimated $1.85K. The largest seller was BlackRock, cutting an estimated $43.2K.

  • 13 institutional investors held Cyclo Therapeutics, Inc. Common Stock (CYTH) as of Q2 2022, unchanged from Q1 2022.
  • Funds reported $795K of Cyclo Therapeutics, Inc. Common Stock stock for Q2 2022, down 42% quarter-over-quarter.
  • 0 funds opened new Cyclo Therapeutics, Inc. Common Stock positions in Q2 2022 and 0 closed out.
  • The largest Cyclo Therapeutics, Inc. Common Stock buyer in Q2 2022 was Tower Research Capital (TRC), an estimated $1.85K added.
  • The largest Cyclo Therapeutics, Inc. Common Stock seller in Q2 2022 was BlackRock, an estimated $43.2K sold.

Based on aggregated 13F filings for Q2 2022.